By continuing to use this site you consent to the use of cookies on your device as described in our
Cookie Policy unless you have disabled them. You can change your Cookie Settings at any time but parts of our site will not function correctly without them.

A drink containing a compound that makes tumour cells glow has helped surgeons in Britain to spot and safely remove brain cancer.

The research was carried out with patients who had suspected glioma, the most common form of brain cancer.

Treatment usually involves surgery to remove as much of the cancer as possible, but it can be challenging for surgeons to identify all of the cancer cells while avoiding healthy brain tissue.

In a trial presented at the 2018 National Cancer Research Institute (NCRI) cancer conference in Glasgow, the researchers said that using the fluorescent marker helped surgeons to distinguish the most aggressive cancer cells from other brain tissue and they hope this will ultimately improve patient survival.

They were aged between 23 and 77 years, with an average (median) age of 59 years.

Before surgery to remove their brain tumours, each patient was given a drink containing 5-ALA.

Surgeons then used operating microscopes to help them look for fluorescent tissue while removing tumours from the patients' brains.

The tissue they removed was sent to the pathology lab where scientists could confirm the accuracy of the surgeons' work.

A total of 99 patients received the 5-ALA marker and could be assessed for signs of fluorescence.

During their operations, surgeons reported seeing fluorescence in 85 patients and 81 of these were subsequently confirmed by pathologists to have high-grade disease, one was found to have low-grade disease and three could not be assessed.

"This is the first prospective trial to show the benefits of using 5-ALA to improve the accuracy of diagnosing high-grade glioma during surgery. These results show that the marker is very good at indicating the presence and location of high-grade cancer cells," Watts added.

--IANS

gb/bg

(This story has not been edited by Business Standard staff and is auto-generated from a syndicated feed.)